NCT03689595Enrolling by invitation
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Source: ClinicalTrials.gov · Last updated 31 Jul 2026
Brief summary (registry, in English)
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 30000 (estimated)
- First submitted
- 20 Sept 2018
- Start date
- Oct 2018
- Primary completion date
- Oct 2033
- Lead sponsor
- Dana-Farber Cancer Institute
- Diseases
- Multiple myeloma
- NCT number
- NCT03689595
What you commit to
- Study type: Observational
- Planned participants: 30000
- From Oct 2018 to the primary completion date, Oct 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.
Age
- Persons under the age of 18 years old
- First-degree relatives would not need to be identified by the participant.
- This study includes all special populations who fall within the eligible high-risk age range, ≥ 30 years of age, including adults unable to consent, pregnant women, and prisoners. These populations will not be excluded as this is a non-therapeutic study.
Other
- Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia
Who the study is looking for
- Age ≥ 30 years
- AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.
- OR
- Those over 18 are also eligible if they have 2 or more family members with a blood cancer
- Screened positive by mass spectrometry in the Ghobrial Lab for SMM or MGUS as part of the Mass General Brigham Biobank arm AND fits one of the following two groups of criteria:
- Age ≥ 30 years
- AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.
- OR • Those over 18 are also eligible if they have 2 or more family members with a blood cancer
- Screened positive by mass spectrometry in the Ghobrial Lab for SMM or MGUS as part of the Mass General Brigham Biobank arm AND fits the criteria listed below:
- Age ≥ 18 years
Age in the registry: 30 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.